Figure 3. PRDX2 knockdown suppresses the tumorigenic capacity of CCSCs. Left panel: A total of 1 × 104 cells dissociated from HCT116/HT29-control or -shPRDX2 CD133+CD44+ CCSCs were subcutaneously injected into the flanks of BALB/c nude mice (n = 8 per group). The incidence and size of subcutaneous tumors were counted and measured. Right panel: The growth of subcutaneous tumors was monitored. The image shows the growth curve of subcutaneous tumors of different cell populations at different time points. The tumor volume data are presented as the means ± SD. Statistical analysis: Student’s t-test, *p < 0.05, **p < 0.01, and ***p < 0.001 vs. shPRDX2-CD133+CD44+ cells.